Nature, Published online: 09 November 2022; doi:10.1038/s41586-022-05425-2
A workflow centred around base-specific in situ sequencing generates detailed maps of, and can phenotypically characterize, the unique set of subclones of cancers.
CellAI is a new software startup currently operating in stealth mode. We are keeping a keen eye on the field of spatial biology.
Nature, Published online: 09 November 2022; doi:10.1038/s41586-022-05425-2
A workflow centred around base-specific in situ sequencing generates detailed maps of, and can phenotypically characterize, the unique set of subclones of cancers.
Akoya: New products and partnerships further accelerate and simplify identification of actionable spatial signatures, creating unprecedented opportunities to improve patient outcomes Ready-to-use
[#item_full_content] Reposted from : [#item_link]
Visiopharm today announces that it will be entering into a research pilot with Massachusetts General Hospital (MGH) to investigate the use of
We haven’t yet pulled the wrapper off of our software. Sign up to stay informed.
CellAI | 302-223-9981 | Copyright All Rights Reserved.